Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a gain of 1.26% on January 23, 2025, outperforming the CSI 300 index by 1.71 percentage points, ranking 10th among 31 sub-industries in the Shenwan classification. Notable performers included offline pharmacies (+6.79%), pharmaceutical distribution (+2.66%), and vaccines (+2.26%), while blood products (+0.58%), medical R&D outsourcing (+0.68%), and in vitro diagnostics (+1.37%) lagged behind [4]. - Takeda's new drug Oveporexton has been proposed for priority review by the National Medical Products Administration (NMPA) in China, aimed at treating narcolepsy type 1 in patients aged 16 and above. The drug has shown positive results in two pivotal Phase 3 studies [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]

（文章来源：证券日报） 证券日报网讯 1月23日，亿帆医药发布公告称，公司全资子公司合肥亿帆生物制药有限公司于2026年1 月22日收到国家药品监督管理局核准签发的注射用硫酸多黏菌素B《药品注册证书》。 ...

人民财讯1月23日电，亿帆医药（002019）1月23日公告，全资子公司合肥亿帆生物制药有限公司于2026 年1月22日收到国家药品监督管理局核准签发的注射用硫酸多黏菌素B的药品注册证书。注射用硫酸多 黏菌素B主要用于治疗碳青霉烯类耐药革兰氏阴性杆菌引起的严重感染的成年患者，包括铜绿假单胞菌 敏感菌株引起的脑膜炎和菌血症。 ...

格隆汇1月23日丨亿帆医药(002019.SZ)公布，全资子公司合肥亿帆生物制药有限公司于2026年1月22日 收到国家药品监督管理局核准签发的注射用硫酸多黏菌素B《药品注册证书》。注射用硫酸多黏菌素B 主要用于治疗碳青霉烯类耐药革兰氏阴性杆菌引起的严重感染的成年患者，包括铜绿假单胞菌敏感菌株 引起的脑膜炎和菌血症。 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2026-007 亿帆医药股份有限公司 5、规格：50万单位 6、药品受理号：CYHS2402222 7、证书编号：2026S00108 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）全资子公司合肥亿帆生物制药 有限公司于2026年1月22日收到国家药品监督管理局核准签发的注射用硫酸多黏 菌素B《药品注册证书》。现将相关情况公告如下： 一、药品注册证书主要信息 1、药品名称：注射用硫酸多黏菌素B 2、剂型：注射剂 3、申请事项：药品注册（境内生产） 4、注册分类：化学药品3类 《药品注册证书》。 截至本报告披露日，除本公司外，中国境内注射用硫酸多黏菌素 B 有 6 家 企业获批上市，另有多家企业处于审评阶段。 根据米内网数据显示，注射用硫酸多黏菌素B 2024年上半年国内销售额为 3.50亿元。 8、药品批准文号：国药准字H20263089 9、药品批准文号有效期：至2031年01月13日 10、上市许可持有人：合肥亿帆生物制药有限公司 ...

Core Viewpoint - The company faced backlash from consumers due to a pricing error that led to forced refunds for products purchased at significantly lower prices than intended [1][2][6]. Group 1: Incident Details - Multiple consumers reported that they were forced to refund purchases of laundry detergent from the company's official flagship store, where a 10 kg pack was mistakenly priced at 6.9 yuan instead of the original price of 90.8 yuan [2][4]. - The pricing error occurred during a brief promotional event that lasted approximately five minutes, leading to numerous complaints on social media [3][6]. - The company acknowledged the issue was due to an internal operational oversight during the SKU change process, which resulted in abnormal orders [6]. Group 2: Company Response - The company issued an apology and provided a 5 yuan cash compensation to affected consumers, citing the pricing error as the reason for the refunds [1][6]. - The company has initiated a process upgrade to enhance price verification and implement multi-level reviews to prevent similar issues in the future [6]. - The company expressed gratitude for media and user oversight and committed to improving service quality [6]. Group 3: Company Background - The company, established in 1994, is a leading player in the daily chemical industry, with a reported annual revenue of 31.241 billion yuan in 2022, reflecting a year-on-year growth of 2.13% [6]. - The company’s product range includes fabric care, dish cleaning, oral care, and personal care items [6].

Core Viewpoint - Yifan Pharmaceutical's product Yilishu is still in the early stages of market introduction in the United States, with procurement volumes dependent on agreements and orders rather than actual terminal sales [1] Group 1 - Yifan Pharmaceutical responded to investor inquiries on January 19, indicating that the procurement volume of Yilishu's U.S. partner is based on agreements and orders [1] - The company noted that Yilishu has been on the U.S. market for less than a year and is currently in the initial ramp-up phase [1]

Core Viewpoint - Yifan Pharmaceutical (002019) has indicated that the number of its shareholders is expected to reach 49,452 by December 31, 2025 [1] Group 1 - The company is actively engaging with investors through interactive platforms [1] - The projected number of shareholders reflects the company's growth and investor interest [1]

Core Insights - The article discusses China's strategy to promote its pharmaceutical products globally, focusing on the role of the National Medical Insurance Administration (NMI) in enhancing the internationalization of the Chinese pharmaceutical industry [1][2]. Group 1: Policy and Framework - The NMI has identified the establishment of an innovative international procurement model for medical supplies as a key focus for 2026, leveraging regional advantages of various procurement platforms [1]. - A systematic policy support framework is being developed through collaboration among multiple departments, including the Ministry of Commerce and the Ministry of Industry and Information Technology, to facilitate the international expansion of pharmaceutical products [2][4]. Group 2: Pricing and Registration Systems - The China Drug Price Registration System was launched in December 2025 to create a transparent pricing mechanism for Chinese pharmaceuticals in international markets, with the first overseas drug price certificate issued in January 2026 [3]. - As of January 16, 2026, the registration system has received applications from 60 companies, covering 22 drugs across various categories, indicating a growing interest in international pricing standards [3]. Group 3: Regional Trade Platforms - Regional trade platforms are being established in areas like Guangxi and Xinjiang to enhance the supply of Chinese pharmaceuticals to Southeast Asia and Central Asia, with the China-ASEAN regional pharmaceutical trading platform already operational [4]. - The China-Central Asia "Central Pharmacy" is set to launch in 2026, aiming to integrate services and improve market penetration in Central Asia [4]. Group 4: Industry Insights and Strategies - Companies like Yifan Pharmaceutical emphasize that international expansion is essential for survival and growth, highlighting the need for differentiated innovative products and strong international partnerships [5][6]. - The industry is witnessing a shift from being a "generic drug production powerhouse" to becoming a "leading exporter of innovative drugs," with significant increases in approved innovative drugs and medical devices [6].

Group 1 - The core point of the article is that Yifan Pharmaceutical (002019) is currently conducting single-machine debugging for HMO [1]